Pricing

Renalytix

0 followers

‌

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the founder and global leader in the new field of bioprognosis™ for kidney health.

Industries

Biotechnology

Headquarters

New York, United States

Employees

51-200

Links

Org chart

James McCullough

CEO

James McCullough

Collapse

Co-Founder

Co-Founder

CTO

Chief Medical Officer

Jed Fulk

Vice President Of Sales

Anna Flynn

Director, Quality System Compliance And Eh&s

Elise Wilfinger

Chief Strategy & Marketing Officer

Katherine Edwards PhD

Senior R&d Scientist

Kate Brennan, CFA

Senior Manager, Strategic Finance

Christopher Scott

Chief Operating Officer

Teams

+11

Management Team

14 members

Healthcare and Clinical Science

7 members

Leadership Team

3 members

Sales Team

3 members

Product Management and Development Team

4 members

Offices

Similar companies

Kura Oncology

20 followers

SpringWorks Therapeutics

6 followers

Biofourmis

6 followers

REVOLUTION Medicines

5 followers

C4 Therapeutics

5 followers

Immunovant

5 followers

Tectonic Therapeutic

4 followers

Stemline Therapeutics

3 followers

Dyne Therapeutics

3 followers

Precigen

3 followers

Arcturus Therapeutics

2 followers

Explore companies